TMBR · Timber Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $73.0K | $100.0K |
| Cost of Revenue | - | - | - | $250.0K | - | - |
| Gross Profit | - | - | - | ($26.0K) | ($177.0K) | ($416.0K) |
| R&D | $9.30M | $6.15M | $2.73M | $9.08M | $9.14M | $10.16M |
| SG&A | $6.02M | $5.39M | $4.06M | $5.24M | $5.14M | $4.65M |
| Total Operating Expenses | $19.32M | $11.54M | $20.67M | $16.48M | $16.70M | $18.01M |
| D&A | $4.1K | $1.4K | $61.0K | $62.0K | $52.0K | $141.0K |
| Operating Income | ($19.24M) | ($10.65M) | ($20.21M) | ($16.51M) | ($16.88M) | ($18.43M) |
| Interest Expense | - | - | - | - | - | $145.0K |
| Income Tax | $7.6K | ($30.2K) | $37.8K | $2.0K | $2.0K | $2.0K |
| Net Income | ($19.38M) | ($10.64M) | ($15.12M) | ($17.26M) | ($16.64M) | ($18.41M) |
| EPS - Basic | ($9.19) | ($0.97) | - | - | - | - |
| EPS - Diluted | ($9.19) | ($0.97) | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.08M | $16.81M | $10.35M | $3.07M | $7.58M | $6.50M |
| Accounts Receivable | - | - | - | $4.0K | $7.0K | $4.0K |
| Inventory | - | - | - | - | $10.0K | $38.0K |
| Accounts Payable | $1.35M | $953.3K | $395.0K | $1.36M | $1.38M | $2.55M |
| Current Assets | $9.81M | $17.12M | $10.73M | $3.38M | $7.98M | $6.83M |
| Total Assets | $10.28M | $17.90M | $11.63M | $3.65M | $8.09M | $7.10M |
| Current Liabilities | $5.04M | $4.19M | $1.38M | $2.30M | $2.98M | $3.73M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $5.04M | $4.63M | $2.11M | $2.36M | $3.02M | $4.13M |
| Stockholders' Equity | $5.23M | $13.27M | $7.61M | $1.30M | $5.07M | $2.97M |
| Retained Earnings | ($48.26M) | ($28.88M) | ($18.25M) | ($78.53M) | ($61.28M) | ($44.64M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($15.85M) | ($9.31M) | ($8.29M) | ($14.99M) | ($15.75M) | ($15.75M) |
| Investing Cash Flow | ($7.1K) | ($17.8K) | ($2.66M) | ($43.0K) | ($45.0K) | ($45.0K) |
| Financing Cash Flow | $8.13M | $15.79M | $21.24M | $10.53M | $18.25M | $18.25M |
| CapEx | $7.1K | $17.8K | $30.0K | $43.0K | $41.0K | $45.0K |
| Free Cash Flow | ($15.86M) | ($9.33M) | ($8.32M) | ($15.04M) | ($15.79M) | ($15.79M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | -242.5% | -416.0% |
| Operating margin | - | - | - | - | -23117.8% | -18426.0% |
| EBITDA margin | - | - | - | - | -23046.6% | -18285.0% |
| Net margin | - | - | - | - | -22794.5% | -18406.0% |
| Free cash flow margin | - | - | - | - | -21626.0% | -15791.0% |
| FCF / Net income | 0.82 | 0.88 | 0.55 | 0.87 | 0.95 | 0.86 |
| R&D / Revenue | - | - | - | - | 12520.5% | 10158.0% |
| SG&A / Revenue | - | - | - | - | 7046.6% | 4654.0% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -188.6% | -59.4% | -130.0% | -472.3% | -205.7% | -259.2% |
| Return on equity | -370.2% | -80.2% | -198.7% | -1329.6% | -328.1% | -619.5% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.95 | 4.08 | 7.76 | 1.47 | 2.68 | 1.83 |
| Quick ratio | 1.95 | 4.08 | 7.76 | 1.47 | 2.68 | 1.82 |
| Cash ratio | 1.80 | 4.01 | 7.49 | 1.34 | 2.54 | 1.74 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | -127.1x |
| Equity multiplier | 1.96 | 1.35 | 1.53 | 2.82 | 1.60 | 2.39 |
| Liabilities / Assets | 0.49 | 0.26 | 0.18 | 0.64 | 0.37 | 0.58 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | 0.01 | 0.01 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | 35d | 15d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | 1990d | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | -27.0% | 56.3% |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | 85.3% | 57.5% | -140.5% |
| Operating income growth (YoY) | -80.6% | 47.3% | -22.5% | 2.2% | 8.4% | -21.6% |
| Net income growth (YoY) | -82.2% | 29.6% | 12.4% | -3.7% | 9.6% | -18.0% |
| EPS growth (YoY) | -847.4% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -70.0% | -12.1% | 44.6% | 4.8% | 0.0% | -24.8% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -60.5% | 74.4% | 486.1% | -74.4% | 70.7% | 44.6% |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Timber Pharmaceuticals against the 5 most active filers in the same SIC group.